Hematologic Oncology

Latest News

January 28th 2019

The ECHELON-2 Trial Presented at ASH 2018

January 28th 2019

Brentuximab Vedotin Overview and Treatment Advice

January 28th 2019

T-Cell Lymphoma Differential Diagnosis and CD30 Treatment

January 28th 2019

Peripheral T-Cell Lymphoma Classifications and CD30 Testing

January 25th 2019

Dr. Oh Discusses the Differences Between Investigational JAK Inhibitors and Ruxolitinib in MPNs

By Stephen Oh, MD, PhD

Latest Videos

The Rationale for Targeting BCMA in Multiple Myeloma

The Rationale for Targeting BCMA in Multiple Myeloma

Treatment Approach for R/R Multiple Myeloma

Treatment Approach for R/R Multiple Myeloma

Jorge E. Cortes, MD, shares advice for navigating among first- and second-generation TKIs in the frontline treatment of patients with chronic myeloid leukemia.

Dr. Cortes on Navigating Among Frontline TKIs in the CML Paradigm

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CML

Gaby Hobbs, MD, of Massachusetts General Hospital

Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CML

Kendra Sweet, MD, of Moffitt Cancer Center

Dr. Sweet on Treatment Selection With TKIs in CML

Eunice Wang, MD

Dr. Wang on Preliminary Findings From the KOMET-001 Trial in Relapsed/Refractory AML

Daniel J. DeAngelo, MD, PhD, of Dana-Farber Cancer Institute

Dr. DeAngelo on the Mechanism of Action of Pevonedistat in MDS

Joshua Brody, MD

Dr. Brody on the Role of Immunotherapy in Hodgkin Lymphoma

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

CME Content

Show Me the Data™: Redefining Extensive-Stage SCLC — Emerging Therapies, CNS Considerations, and the Radiation Oncologist's Evolving Role

Show Me the Data™: Redefining Extensive-Stage SCLC — Emerging Therapies, CNS Considerations, and the Radiation Oncologist's Evolving Role

October 29, 2026

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Wisconsin Association of Hematology and Oncology

Virginia Kaklamani, MD, DSc; Girish Kunapareddy, MD

New Mexico Society of Clinical Oncology

New Mexico Society of Clinical Oncology

1 Session is Available!

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Wyoming State Oncology Society & Montana State Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Wyoming State Oncology Society & Montana State Oncology Society

Sarah M. Tolaney, MD, MPH; Yelda Nouri, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Indiana Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Indiana Oncology Society

Geoffrey Ku, MD; Girish Kunapareddy, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Rhode Island Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Rhode Island Oncology Society

Shiven Patel, MD, MBA, FACP; Sunnie S. Kim, MD

Colorado Oncology Society

Colorado Oncology Society

1 Session is Available!

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors – Kansas Society of Clinical Oncology

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors – Kansas Society of Clinical Oncology

Mrinal M. Gounder, MD; Madhuri Yalamanchili, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | New Mexico Society of Clinical Oncology

Benjamin Scheier, MD; Syma Iqbal, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Iowa Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Iowa Oncology Society

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Rhode Island Oncology Society

Rhode Island Oncology Society

1 Session is Available!

44th Annual CFS®: Innovative Cancer Therapy for Tomorrow™

In-Person + Virtual Event

44th Annual CFS®: Innovative Cancer Therapy for Tomorrow™

November 11-13, 2026

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Minnesota Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Minnesota Society of Clinical Oncology

Kate Baxstrom, MD; Virginia Kaklamani, MD, DSc

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Empire State Hematology and Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Empire State Hematology and Oncology Society

Jack W. Erter III, MD, MMHC; Geoffrey Ku, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Frantz Francisque, MD; Jacob Sands, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Komal Jhaveri, MD, FACP; Ruta D. Rao, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Kentucky Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Kentucky Society of Clinical Oncology

Sunnie S. Kim, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | South Carolina Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | South Carolina Oncology Society

Geoffrey Ku, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Texas Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Texas Society of Clinical Oncology

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Neil M. Iyengar, MD; Kit Lu, MD

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Project ECHO®: Advancing Personalized Care Across the HR+/HER2– Breast Cancer Continuum

Webinar Series

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

1 Session is Available!

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Michigan Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Michigan Regional Program

Jacob Sands, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Sarah M. Tolaney, MD, MPH; Parth Khade, MD

South Carolina Oncology Society

South Carolina Oncology Society

1 Session is Available!

Texas Society of Clinical Oncology

Texas Society of Clinical Oncology

1 Session is Available!

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Neil M. Iyengar, MD; Richard Zelkowitz, MD

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Benjamin Scheier, MD; Christine L. Hann, MD, PhD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

Amy E. Armstrong, MD; Anu Batra, MD

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Daniela A. Bota, MD, PhD; Shiven Patel, MD, MBA

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Daniela A. Bota, MD, PhD; Maya Hrachova, DO

Washington State Medical Oncology Society

Washington State Medical Oncology Society

2 Sessions are Available!

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

Wyoming State Oncology Society

Wyoming State Oncology Society

2 Sessions are Available!

Kentucky Society of Clinical Oncology

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

3 Sessions are Available!

Minnesota Society of Clinical Oncology

Minnesota Society of Clinical Oncology

1 Session is Available!

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

1 Session is Available!

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Nevada Oncology Society

Nevada Oncology Society

3 Sessions are Available!

Missouri Oncology Society

Missouri Oncology Society

2 Sessions are Available!

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Neil M. Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; Wassim Mchayleh, MD, MBA, FACP

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD; Jonathan Strosberg, MD

Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice

Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice

Eunice Wang, MD; Hetty Carraway, MD, MBA; Naval G. Daver, MD

More News

Blood Cancers Associated With Higher Treatment and Out-of-Pocket Costs

January 25th 2019

Patients with blood cancers face greater treatment costs than those with solid tumors. Furthermore, healthcare spending for these patients is already higher than average before diagnosis and does not return to prediagnosis levels even after successful treatment.

The Future of ITP Treatment

January 24th 2019

Rituximab and Salvage Therapies for Patients With ITP

January 24th 2019

TPO Duration of Response and Toxicity

January 24th 2019

TPO Receptor Agonist Selection and Patient Adherence

January 24th 2019

Romiplostim Classification and Mechanism of Action

January 24th 2019

Fostamatinib as Second-Line ITP Therapy

January 24th 2019

Second-Line Treatment Options for Patients with ITP

January 24th 2019

Steroid Combination Therapy & New ASH Guidelines

January 24th 2019

First-Line Therapy Options for Patients with ITP

January 24th 2019

ITP Patient Management and Important Treatment Factors

January 24th 2019

ITP Treatment Selection Criteria and Treatment Goals

January 24th 2019

ITP Pathogenesis, Presentation, and Diagnostic Workup

January 24th 2019

Future Treatment Strategies in Adult ALL

January 22nd 2019

Evaluating CAR T Therapy in Acute Lymphoblastic Leukemia

January 22nd 2019

When to Use Inotuzumab Ozogamicin for Adult ALL

January 22nd 2019

Selecting a Novel Therapy for Relapsed/Refractory ALL

January 22nd 2019

Allogeneic Transplant at First Remission of ALL

January 22nd 2019

Establishing MRD's Role in ALL Management

January 22nd 2019

Blinatumomab: Safety Data in Ph-Negative ALL

January 22nd 2019

Ph-Negative ALL: Establishing Blinatumomab's Role in Therapy

January 22nd 2019

Treatment Algorithms for Philadelphia-Negative ALL

January 22nd 2019

Approaching the Management of Philadelphia-Negative ALL

January 22nd 2019

Acute Lymphocytic Leukemia: What's Next

January 22nd 2019

Examining the Toxicities of CAR T-cell Therapy

January 22nd 2019

Trending on OncLive

Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC

Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos

FDA Receives BLA for Etentamig in R/R Multiple Myeloma

Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC

Phase 3 IMpactMF Trial Evaluating Imetelstat in R/R Myelofibrosis Is Discontinued